Clinical Efficacy of Fuyang Huaji Formula and Tislelizumab in the Treatment of Non-small Cell Lung Cancer

JIANG Xiaoxia; SHU Xingwei; YE Yong

doi:10.14033/j.cnki.cfmr.2025.13.001

Abstract：Objective:To explore the clinical efficacy of the combination of Fuyang Huaji Formula and Tislelizumab in the treatment of non-small cell lung cancer(NSCLC).Method:Eighty patients with NSCLC treated in Honghu Traditional Chinese Medicine Hospital from March 2022 to December 2023 were selected and divided into study group(n=40)and control group(n=40)by random number table method.The control group was treated with Tislelizumab,and the study group was treated with Fuyang Huaji Formula combined with Tislelizumab.The clinical efficacy,traditional Chinese medicine symptom score,tumor markers[squamous cell carcinoma antigen(SCC),carbohydrate antigen 199(CA199),carbohydrate antigen 125(CA125)],cellular immune function[T lymphocyte subsets(CD3+,CD4+,CD8+)]and incidence of adverse reactions were compared between the two groups.Result:The objective response rate(ORR)and disease control rate(DCR)of the study group were higher than those of the control group,and the differences were statistically significant(P<0.05).The scores of traditional Chinese medicine symptoms of the two groups decreased after treatment,and the study group was lower than the control group,the differences were statistically significant(P<0.05).After treatment,the levels of SCC,CA199 and CA125 decreased in the two groups,and the levels in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,CD3+and CD4+increased and CD8+decreased in the two groups,the CD3+and CD4+in the study group were higher than those in the control group,and CD8+was lower,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group was 15.00%(6/40),which was lower than 40.00%(16/40)in the control group,and the difference was statistically significant(P<0.05).Conclusion:The combination of Fuyang Huaji Formula and Tislelizumab in the treatment of NSCLC patients can improve clinical efficacy,reduce traditional Chinese medicine syndrome scores and tumor marker levels,improve cellular immune function,and reduce the occurrence of adverse reactions.